Skip to content
Screener

CRISPR Therapeutics CRSP Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$107.42M-5.7%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$43.06M+27.8%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$96.5M+11.3%
Prime Medicine logo
Prime MedicinePRME
-$42.12M+19.9%
Regenxbio logo
RegenxbioRGNX
$22.7M+132%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$5.33M-103%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$5.17B+2.7%
Enterprise value$5.54B+9.4%
P/S1,261.3×+1,129×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:48 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204188
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Net loss(122,931)(135,996)
Foreign currency translation adjustment(32)41
Unrealized (loss) gain on marketable securities(6,730)2,254
Comprehensive loss$(129,693)$(133,701)
Net loss per common share — basic$(1.28)$(1.58)
Basic weighted-average common shares outstanding96,051,22885,938,720
Net loss per common share — diluted$(1.28)$(1.58)
Diluted weighted-average common shares outstanding96,051,22885,938,720

Item 1. Financial Statements

FAQ

What is CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
CRISPR Therapeutics (CRSP) reported comprehensive income (loss), net of tax, attributable to parent of -$129.69M in Q1 2026.
How has CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent increased by 3.0% year-over-year, from -$133.7M to -$129.69M.
What is the long-term trend for CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2022 to 2025), CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a -6.4% compound annual growth rate (CAGR), from -$660.75M to -$578.62M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This represents the total change in equity from non-owner sources, including net income and other comprehensive income items like foreign currency adjustments and unrealized gains on securities. It provides a more holistic view of the company's financial health than net income alone by capturing broader economic impacts. Investors use this to evaluate the total impact of all financial activities on the company's net worth.

Ask your AI about CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude